RC
UTHR icon

RegentAtlantic Capital’s United Therapeutics UTHR Stock Holding History

RegentAtlantic Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$699K Sell
3,340
-389
-10% -$87K 0.02% 378
2022
Q2 		$879K Sell
3,729
-395
-10% -$80.3K 0.03% 338
2022
Q1 		$740K Sell
4,124
-288
-7% -$54.9K 0.02% 373
2021
Q4 		$953K Sell
4,412
-137
-3% -$26.9K 0.03% 331
2021
Q3 		$840K Sell
4,549
-983
-18% -$194K 0.03% 332
2021
Q2 		$992K Sell
5,532
-1,354
-20% -$258K 0.03% 295
2021
Q1 		$1.15M Sell
6,886
-641
-9% -$107K 0.04% 259
2020
Q4 		$1.14M Buy
7,527
+1,411
+23% +$185K 0.05% 228
2020
Q3 		$618K Buy
6,116
+2,962
+94% +$325K 0.03% 294
2020
Q2 		$382K Buy
+3,154
New +$355K 0.02% 342
2019
Q3 		– Sell
-3,378
Closed -$264K – 458
2019
Q2 		$264K Sell
3,378
-1,715
-34% -$160K 0.02% 378
2019
Q1 		$598K Sell
5,093
-50
-1% -$5.83K 0.04% 271
2018
Q4 		$560K Sell
5,143
-526
-9% -$61K 0.05% 268
2018
Q3 		$725K Sell
5,669
-498
-8% -$61.6K 0.06% 255
2018
Q2 		$698K Sell
6,167
-2,265
-27% -$249K 0.06% 249
2018
Q1 		$947K Sell
8,432
-3,777
-31% -$480K 0.08% 217
2017
Q4 		$1.81M Sell
12,209
-714
-6% -$90.8K 0.15% 157
2017
Q3 		$1.51M Buy
12,923
+315
+2% +$40.2K 0.13% 168
2017
Q2 		$1.64M Sell
12,608
-1,795
-12% -$224K 0.15% 153
2017
Q1 		$1.95M Sell
14,403
-1,130
-7% -$171K 0.18% 141
2016
Q4 		$2.23M Buy
15,533
+2,785
+22% +$356K 0.22% 124
2016
Q3 		$1.5M Sell
12,748
-815
-6% -$97.9K 0.16% 150
2016
Q2 		$1.44M Buy
13,563
+1,285
+10% +$143K 0.14% 148
2016
Q1 		$1.37M Buy
+12,278
New +$1.55M 0.15% 140
2015
Q1 		– Sell
-313
Closed -$40.5K – 917
2014
Q4 		$40.5K Buy
+313
New +$40.3K ﹤0.01% 628

Other funds holding UTHR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RegentAtlantic Capital's UTHR Position: Q3 2022 in Review

RegentAtlantic Capital reduced its United Therapeutics (UTHR) stake by 10% in Q3 2022, selling an estimated $87K and leaving 3,340 shares worth $699K. The position accounts for 0.02% of the portfolio, ranked #378.

RegentAtlantic Capital first reported a position in UTHR in Q4 2014 and has held it in 25 quarters since. The position peaked at $2.23M in Q4 2016. 461 funds tracked by Wall St. Rank hold UTHR as of Q3 2022.

  • RegentAtlantic Capital held 3,340 shares of United Therapeutics worth $699K as of Q3 2022.
  • RegentAtlantic Capital sold 389 United Therapeutics shares in Q3 2022, an estimated $87K.
  • United Therapeutics made up 0.02% of RegentAtlantic Capital's portfolio in Q3 2022, its #378 holding.
  • RegentAtlantic Capital first reported a position in United Therapeutics in Q4 2014 and has held it in 25 quarters since.
  • RegentAtlantic Capital's United Therapeutics position peaked at $2.23M in Q4 2016.
  • 461 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2022.

Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.